Lv1
48 积分 2021-03-04 加入
Design of a Fc-engineered tetravalent bispecific antibody targeting PD-1 and VEGF with cooperative biological effects
2个月前
已关闭
Design of a Fc-engineered tetravalent bispecific antibody targeting PD-1 and VEGF with cooperative biological effects
2个月前
已完结
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
3个月前
已完结
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
3个月前
已完结
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
5个月前
已完结
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
5个月前
已完结
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors
5个月前
已关闭
TOX is expressed by exhausted and polyfunctional human effector memory CD8 + T cells
6个月前
已完结
Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
6个月前
已完结
Advancements in the management of obesity: a review of current evidence and emerging therapiesssss
8个月前
已完结
皖公网安备34019202002308
